Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 223, Issue 1-2, Pages 55-64Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2010.04.002
Keywords
Chondroitin sulfate; Immune modulation; Cytokines; Cell migration; EAE/MS
Categories
Funding
- NIH [R01ES09098, R01DA016545, P01AT003961, R01AI053703, R01AI058300, R01HL058641]
- National Center for Complementary & Integrative Health [P01AT003961] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058641] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058300, R01AI053703] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009098, R01ES019313] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016545] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Clinical symptoms in MOG-induced EAE mice significantly exacerbated following chondroitin sulfate A (CS-A) injection, whereas administration of a degraded product, CSPG-DS, caused dramatic inhibition of EAE development. Also, administration of CSPG-DS but not CS-A, after the onset of clinical symptoms of EAE, was able to suppress the disease. Further studies demonstrated that CS-A up-regulated STAT4 expression and thus, induced IFN-gamma production and Th1 CD4T cell differentiation. CS-A also up-regulated STAT3 and IL-23 expression and thus increased IL-17 producing T cells. CSPG-DS treatment both in vivo and in vitro decreased TNF alpha production from splenocytes. In vitro and in vivo studies indicated that CSPG-DS treatment in EAE mice significantly blocked migration of lymphocytes, whereas CS-A treatment increased lymphocyte infiltration in the brain. (C) 2010 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available